Once considering the immunosuppressive effects of the MAPK pathway, it can be hypothesized that BRAF/MEK inhibition, although not designed to target the immune system, influences the tumor-immune microenvironment and anti-tumor immune responses [105]. This evidence concerns the gene BRAF and neoplasm.